Marine-Derived Inhibitors of MMP-2 and MMP-9: Emerging Therapeutic Strategies Against Cancer

Authors

  • Avinaba Mukherjee Department of Zoology, Charuchandra College, University of Calcutta, Kolkata-700029, India.

Keywords:

Matrix metalloproteinase (MMP)-2 and-9, Metastasis, Anticancer, antioxidant, antimicrobial, DPPH, marine algae, seaweeds.

Abstract

Cancer metastasis remains the principal cause of cancer-related mortality and represents one of the greatest challenges in effective cancer therapy. A critical event in the metastatic cascade is the dysregulated expression and activity of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, which degrade extracellular matrix components and facilitate tumor cell invasion, migration, and dissemination. These gelatinases interact with multiple signaling pathways and regulatory molecules, thereby promoting the invasion of cancer cells from the primary tumor into surrounding tissues and distant organs, ultimately leading to the formation of secondary tumors. Consequently, selective inhibition of MMP-2 and MMP-9 has emerged as a promising therapeutic strategy for preventing cancer progression and metastasis. In recent years, natural products derived from medicinal plants, their bioactive phytochemicals, and marine organisms have attracted considerable attention due to their ability to modulate MMP activity with improved target specificity and reduced toxicity. These natural compounds can suppress MMP-2 and MMP-9 expression or activity, thereby inhibiting cancer cell migration, invasion, angiogenesis, and metastatic spread while promoting apoptosis, sparing normal cells. This review summarizes the current understanding of the biological roles of MMP-2 and MMP-9 in carcinogenesis and metastasis. It also critically evaluates the therapeutic potential of marine-derived natural products as inhibitors of these metalloproteinases. A comprehensive understanding of the molecular mechanisms underlying MMP-2 and MMP-9 regulation and their modulation by natural compounds may facilitate the development of novel, effective, and safer anti-metastatic therapies for cancer management.

References

M. Chang, "Matrix metalloproteinase profiling and their roles in disease," RSC Advances, vol. 13, no. 9, pp. 6304–6316, 2023, doi: 10.1039/D2RA07005G.

M. Wolosowicz, S. Prokopiuk, and T. W. Kaminski, "The Complex Role of Matrix Metalloproteinase-2 (MMP-2) in Health and Disease," International Journal of Molecular Sciences, vol. 25, no. 24, Art. no. 13691, 2024, doi: 10.3390/ijms252413691.

K. Brew and H. Nagase, "The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity," Biochimica et Biophysica Acta, vol. 1803, no. 1, pp. 55–71, 2010, doi: 10.1016/j.bbamcr.2010.01.003.

J. Vandooren, P. E. Van den Steen, and G. Opdenakker, "Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade," Critical Reviews in Biochemistry and Molecular Biology, vol. 48, no. 3, pp. 222–272, 2013, doi: 10.3109/10409238.2013.770819.

T. Itoh, M. Tanioka, H. Yoshida, T. Yoshioka, H. Nishimoto, and S. Itohara, "Reduced angiogenesis and tumor progression in gelatinase A-deficient mice," Cancer Research, vol. 58, no. 5, pp. 1048–1051, 1998.

E. I. Deryugina and J. P. Quigley, "Matrix metalloproteinases and tumor metastasis," Cancer Metastasis Reviews, vol. 25, no. 1, pp. 9–34, 2006, doi: 10.1007/s10555-006-7886-9.

L. M. Coussens, B. Fingleton, and L. M. Matrisian, "Matrix metalloproteinase inhibitors and cancer: Trials and tribulations," Science, vol. 295, no. 5564, pp. 2387–2392, 2002, doi: 10.1126/science.1067100.

J. A. Jacobsen, J. L. Major Jourden, M. T. Miller, and S. M. Cohen, "To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition," Biochimica et Biophysica Acta, vol. 1803, no. 1, pp. 72–94, 2010, doi: 10.1016/j.bbamcr.2009.08.006.

V. Rani, D. Yadav, and N. Atale, "Matrix metalloproteinase inhibitors: Promising therapeutic targets against cancer," Current Pharmaceutical Design, vol. 27, no. 45, pp. 4557–4567, 2021, doi: 10.2174/1381612827666210830103059.

N. V. Thomas, A. S. Monica Diyya, S. K. Kim, K. A. Faraj, D. D. Ghafoor, Z. J. Qian, and B. M. Tigabu, "Bioactives from marine organisms and their potential role as matrix metalloproteinase inhibitors," Current Pharmaceutical Design, vol. 28, no. 41, pp. 3351–3362, 2022, doi: 10.2174/1381612829666221121145614.

S. O. Oselusi, N. R. Sibuyi, D. R. Martin, M. Meyer, and A. M. Madiehe, "Potential matrix metalloproteinase 2 and 9 inhibitors identified from Ehretia species for the treatment of chronic wounds—Computational drug discovery approaches," Computers in Biology and Medicine, vol. 185, Art. no. 109487, 2025, doi: 10.1016/j.compbiomed.2024.109487.

Q. X. Sang, Y. Jin, R. G. Newcomer, S. C. Monroe, X. Fang, D. R. Hurst, S. Lee, Q. Cao, and M. A. Schwartz, "Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases," Current Topics in Medicinal Chemistry, vol. 6, no. 4, pp. 289–316, 2006, doi: 10.2174/156802606776287045.

J. Hu, P. E. Van den Steen, Q. X. Sang, and G. Opdenakker, "Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases," Nature Reviews Drug Discovery, vol. 6, no. 6, pp. 480–498, 2007, doi: 10.1038/nrd2308.

M. Jiang and Z. Zhu, "The role of artificial intelligence algorithms in marine scientific research," Frontiers in Marine Science, vol. 9, Art. no. 920994, 2022, doi: 10.3389/fmars.2022.920994.

H. Nagase, R. Visse, and G. Murphy, "Structure and function of matrix metalloproteinases and TIMPs," Cardiovascular Research, vol. 69, no. 3, pp. 562–573, 2006, doi: 10.1016/j.cardiores.2005.12.002.

C. Tallant, A. Marrero, and F. X. Gomis-Rüth, "Matrix metalloproteinases: Fold and function of their catalytic domains," Biochimica et Biophysica Acta, vol. 1803, no. 1, pp. 20–28, 2010, doi: 10.1016/j.bbamcr.2009.04.003.

G. Murphy and H. Nagase, “Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: Destruction or repair?,” Nature Clinical Practice Rheumatology, vol. 4, no. 3, pp. 128–135, 2008, doi: 10.1038/ncprheum0727. P. Vihinen, R. Ala-aho, and V. M. Kähäri, “Matrix metalloproteinases as therapeutic targets in cancer,” Current Cancer Drug Targets, vol. 5, no. 3, pp. 203–220, 2005, doi: 10.2174/1568009053765799.

P. Cancemi, A. Aiello, G. Accardi, R. Caldarella, G. Candore, C. Caruso, M. Ciaccio, L. Cristaldi, F. Di Gaudio, V. Siino, and S. Vasto, “The role of matrix metalloproteinases (MMP-2 and MMP-9) in ageing and longevity: Focus on Sicilian long-living individuals (LLIs),” Mediators of Inflammation, vol. 2020, Art. no. 8635158, 2020, doi: 10.1155/2020/8635158.

H. Jiang and H. Li, “Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: A systematic review and meta-analysis,” BMC Cancer, vol. 21, no. 1, Art. no. 149, 2021, doi: 10.1186/s12885-021-07860-2.

G. Bergers and L. E. Benjamin, “Tumorigenesis and the angiogenic switch,” Nature Reviews Cancer, vol. 3, no. 6, pp. 401–410, 2003, doi: 10.1038/nrc1093.

S. P. Gupta and V. M. Patil, “Specificity of binding with matrix metalloproteinases,” Experimental Supplements, vol. 103, pp. 35–56, 2012, doi: 10.1007/978-3-0348-0364-9_2.

A. Page-McCaw, A. J. Ewald, and Z. Werb, “Matrix metalloproteinases and the regulation of tissue remodelling,” Nature Reviews Molecular Cell Biology, vol. 8, no. 3, pp. 221–233, 2007, doi: 10.1038/nrm2125.

Q. Ebrahem, S. S. Chaurasia, A. Vasanji, J. H. Qi, P. A. Klenotic, A. Cutler, K. Asosingh, S. Erzurum, and B. Anand-Apte, “Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo,” American Journal of Pathology, vol. 176, no. 1, pp. 496–503, 2010, doi: 10.2353/ajpath.2010.080642.

D. Lotrian, J.-P. Campion, P. Bioulac-Sage, K. Boudjéma, O. Musso, B. Turlin, N. Théret, and B. Clément, “Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas,” Hepatology, vol. 34, no. 1, pp. 82–88, 2001, doi: 10.1053/jhep.2001.25758.

M. W. Roomi, J. C. Monterrey, T. Kalinovsky, M. Rath, and A. Niedzwiecki, “Patterns of MMP-2 and MMP-9 expression in human cancer cell lines,” Oncology Reports, vol. 21, no. 5, pp. 1323–1333, 2009, doi: 10.3892/or_00000358.

H. Li, Z. Qiu, F. Li, and C. Wang, “The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis,” Oncology Letters, vol. 14, no. 5, pp. 5865–5870, 2017, doi: 10.3892/ol.2017.6924.

K. Shchors, H. Nozawa, J. Xu, F. Rostker, L. Swigart-Brown, G. Evan, and D. Hanahan, “Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis,” Oncogene, vol. 32, no. 4, pp. 502–513, 2013, doi: 10.1038/onc.2012.60.

K. Kessenbrock, V. Plaks, and Z. Werb, “Matrix metalloproteinases: Regulators of the tumor microenvironment,” Cell, vol. 141, no. 1, pp. 52–67, 2010, doi: 10.1016/j.cell.2010.03.015.

C. Gialeli, A. D. Theocharis, and N. K. Karamanos, “Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting,” FEBS Journal, vol. 278, no. 1, pp. 16–27, 2011, doi: 10.1111/j.1742-4658.2010.07919.x.

M. T. Islam, N. H. Jang, and H. J. Lee, “Natural products as regulators against matrix metalloproteinases for the treatment of cancer,” Biomedicines, vol. 12, no. 4, Art. no. 794, 2024, doi: 10.3390/biomedicines12040794.

F. Karadeniz, S. G. Lee, J. H. Oh, et al., “Inhibition of MMP-2 and MMP-9 activities by solvent-partitioned Sargassum horneri extracts,” Fisheries and Aquatic Sciences, vol. 21, Art. no. 16, 2018, doi: 10.1186/s41240-018-0093-0.

C. S. Kong, Y. A. Kim, M. M. Kim, J. S. Park, J. A. Kim, S. K. Kim, B. J. Lee, T. J. Nam, and Y. Seo, “Flavonoid glycosides isolated from Salicornia herbacea inhibit matrix metalloproteinase in HT1080 cells,” Toxicology In Vitro, vol. 22, no. 7, pp. 1742–1748, 2008, doi: 10.1016/j.tiv.2008.07.013.

H. Zheng, Y. Pei, Y. L. He, Y. Liu, M. Chen, P. Hong, C. Zhou, and Z. J. Qian, “A sulfated polysaccharide from red algae (Gelidium crinale) to suppress cells metastasis and MMP-9 expression of HT1080 cells,” Foods, vol. 11, no. 15, Art. no. 2360, 2022, doi: 10.3390/foods11152360.

C. Mirand, “Inhibition of gelatinase A by oleic acid,” Annals of the New York Academy of Sciences, 1999, doi: 10.1111/J.1749-6632.1999.TB07751.X.

M. H. Wu, Y. T. Tsai, K. T. Hua, K. C. Chang, M. L. Kuo, and M. T. Lin, “Eicosapentaenoic acid and docosahexaenoic acid inhibit macrophage-induced gastric cancer cell migration by attenuating the expression of matrix metalloproteinase 10,” Journal of Nutritional Biochemistry, vol. 23, no. 11, pp. 1434–1439, 2012, doi: 10.1016/j.jnutbio.2011.09.004.

G. Calviello, S. Serini, and E. Piccioni, “n-3 polyunsaturated fatty acids and the prevention of colorectal cancer: Molecular mechanisms involved,” Current Medicinal Chemistry, vol. 14, no. 29, pp. 3059–3069, 2007, doi: 10.2174/092986707782793934.

D. Varijakzhan, J. Y. Loh, W. S. Yap, K. Yusoff, R. Seboussi, S. E. Lim, K. S. Lai, and C. M. Chong, “Bioactive compounds from marine sponges: Fundamentals and applications,” Marine Drugs, vol. 19, no. 5, Art. no. 246, 2021, doi: 10.3390/md19050246.

M. Fujita, Y. Nakao, S. Matsunaga, R. W. van Soest, Y. Itoh, M. Seiki, and N. Fusetani, “Callysponginol sulfate A, an MT1-MMP inhibitor isolated from the marine sponge Callyspongia truncata,” Journal of Natural Products, vol. 66, no. 4, pp. 569–571, 2003, doi: 10.1021/np020572s.

G. Ahn, W. Lee, K. N. Kim, J. H. Lee, S. J. Heo, N. Kang, S. H. Lee, C. B. Ahn, and Y. J. Jeon, “A sulfated polysaccharide of Ecklonia cava inhibits the growth of colon cancer cells by inducing apoptosis,” EXCLI Journal, vol. 14, pp. 294–306, 2015, doi: 10.17179/excli2014-676.

N. V. Thomas, P. Manivasagan, and S. K. Kim, “Potential matrix metalloproteinase inhibitors from edible marine algae: A review,” Environmental Toxicology and Pharmacology, vol. 37, no. 3, pp. 1090–1100, 2014, doi: 10.1016/j.etap.2014.04.011.

M. M. Kim, Q. V. Ta, E. Mendis, N. Rajapakse, W. K. Jung, H. G. Byun, Y. J. Jeon, and S. K. Kim, “Phlorotannins in Ecklonia cava extract inhibit matrix metalloproteinase activity,” Life Sciences, vol. 79, no. 15, pp. 1436–1443, 2006, doi: 10.1016/j.lfs.2006.04.022.

P. Koirala, H. A. Jung, and J. S. Choi, “Recent advances in pharmacological research on Ecklonia species: A review,” Archives of Pharmacal Research, vol. 40, no. 9, pp. 981–1005, 2017, doi: 10.1007/s12272-017-0948-4.

D. Matulja, F. Vranješević, M. Kolympadi Markovic, S. K. Pavelić, and D. Marković, “Anticancer activities of marine-derived phenolic compounds and their derivatives,” Molecules, vol. 27, no. 4, Art. no. 1449, 2022, doi: 10.3390/molecules27041449.

M. T. Ale, J. D. Mikkelsen, and A. S. Meyer, “Important determinants for fucoidan bioactivity: A critical review of structure-function relations and extraction methods for fucose-containing sulfated polysaccharides from brown seaweeds,” Marine Drugs, vol. 9, no. 10, pp. 2106–2130, 2011, doi: 10.3390/md9102106.

S. Zorofchian Moghadamtousi, H. Karimian, R. Khanabdali, M. Razavi, M. Firoozinia, K. Zandi, and H. Abdul Kadir, “Anticancer and antitumor potential of fucoidan and fucoxanthin, two main metabolites isolated from brown algae,” The Scientific World Journal, vol. 2014, Art. no. 768323, 2014, doi: 10.1155/2014/768323.

C. Zhang and S. K. Kim, “Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: The current situation and future prospects,” Marine Drugs, vol. 7, no. 2, pp. 71–84, 2009, doi: 10.3390/md7020071.

D. Gingras, G. Batist, and R. Béliveau, “AE-941 (Neovastat): A novel multifunctional antiangiogenic compound,” Expert Review of Anticancer Therapy, vol. 1, no. 3, pp. 341–347, 2001, doi: 10.1586/14737140.1.3.341.

J. Venkatesan, S. Anil, S. K. Kim, and M. S. Shim, “Marine fish proteins and peptides for cosmeceuticals: A review,” Marine Drugs, vol. 15, no. 5, Art. no. 143, 2017, doi: 10.3390/md15050143.

G. K. Ostrander, K. C. Cheng, J. C. Wolf, and M. J. Wolfe, “Shark cartilage, cancer and the growing threat of pseudoscience,” Cancer Research, vol. 64, no. 23, pp. 8485–8491, 2004, doi: 10.1158/0008-5472.CAN-04-2260.

A. R. Carroll, B. R. Copp, T. Grkovic, R. A. Keyzers, and M. R. Prinsep, “Marine natural products,” Natural Product Reports, vol. 43, no. 1, pp. 89–131, 2026, doi: 10.1039/D5NP00080G.

A. Winer, S. Adams, and P. Mignatti, “Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes,” Molecular Cancer Therapeutics, vol. 17, no. 6, pp. 1147–1155, 2018, doi: 10.1158/1535-7163.MCT-17-0646.

G. Li, P. Lin, K. Wang, C. C. Gu, and S. Kusari, “Artificial intelligence-guided discovery of anticancer lead compounds from plants and associated microorganisms,” Trends in Cancer, vol. 8, no. 1, pp. 65–80, 2022, doi: 10.1016/j.trecan.2021.

A. Shenouda, S. Senthilkumar, Y. Mourad, J. Xie, E. Peker, S. Zeeshan, and Z. Ahmed, “Artificial intelligence to investigate metabolomics data for precision medicine,” Metabolomics, vol. 22, no. 2, Art. no. 29, 2026, doi: 10.1007/s11306-026-02401-z.

R. E. Vandenbroucke and C. Libert, “Is there new hope for therapeutic matrix metalloproteinase inhibition?,” Nature Reviews Drug Discovery, vol. 13, no. 12, pp. 904–927, 2014, doi: 10.1038/nrd4390.

H. Laronha, I. Carpinteiro, J. Portugal, A. Azul, M. Polido, K. T. Petrova, M. Salema-Oom, and J. Caldeira, “Challenges in matrix metalloproteinases inhibition,” Biomolecules, vol. 10, no. 5, Art. no. 717, 2020, doi: 10.3390/biom10050717.

Published

2026-11-02

How to Cite

Mukherjee, A. (2026). Marine-Derived Inhibitors of MMP-2 and MMP-9: Emerging Therapeutic Strategies Against Cancer. International Journal of Life Science and Pharma Research, 16(3). Retrieved from https://www.ijlpr.com/index.php/journal/article/view/2050

Issue

Section

Review Articles